Experimental cancer drug shows promise. The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. Source 8q.
This site uses Cookies to dispense or record information with regards to your visit. By continuing to use this site you agree to the terms outlined in ourCookies used here:Privacy / Disclaimer,